<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892447</url>
  </required_header>
  <id_info>
    <org_study_id>SJES001</org_study_id>
    <nct_id>NCT03892447</nct_id>
  </id_info>
  <brief_title>The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury</brief_title>
  <official_title>A 52-week Multicenter, Randomized, Double-blind, Prospective Study to Evaluate Comparative Effectiveness and Safety of Alprostadil Injection,Sodium Ferulate and Dopamine Injection in Pediatric Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) is a pervasive clinical event in children.It has been independently
      associated with prolonged hospital stays, risk of in-hospital death and future progression to
      chronic kidney disease. Except for removal of nephrotoxic agents and optimization of
      supportive care,there are still no other effective therapeutic options recommended by recent
      guidelines. Renal ischemia is the main mechanism of AKI, the improving microcirculation
      therapy would be the effective management to improve the outcome of AKI in children.

      Dopamine is a vasodilating drug that in small doses improves renal circulation. Alprostadil
      have been used in chronic arterial occlusion and Sodium Ferulate in ischemic cerebral
      vascular disease,they have a similar therapeutic effect of anti-platelet aggregation and
      vasodilation. Recent research shows that alprostadil might be associated with a significant
      reduction in postcontrast Scr, blood urine nitrogen (BUN) and Cystatin C (CysC) level and
      decrease the incidence of contrast-induced nephropathy.The investigators speculate that
      Alprostadil,Sodium Ferulate and dopamine would be effective in treating AKI in children.

      This is a prospective, multicenter, randomized, double-blind, 52-week study. The purpose of
      this study is to evaluate the comparative effectiveness and safety of Alprostadil,Sodium
      Ferulate and dopamine in improving the outcome of AKI in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to explore the effective treatment of pediatric AKI and improve the outcome.
      It is a 52-week multicenter, randomized, double-blind,prospective study to evaluate
      comparative effectiveness and safety of alprostadil injection,sodium ferulate and dopamine
      injection. This study plans to recruit 8 to 10 centers, with 300 participants randomly
      divided into 3 groups and given respectively Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d,Sodium
      Ferulate2~6mg/kg.d,iv,14d,Dopamine3~5ug/kg .min,iv,3h/d,14d.Time of outcome measurement is
      1w,2w,4w,24w,52w. Primary Outcome Measures is The change of Serum creatinin from baseline,
      estimated glomerular filtration rate (eGFR) and urine volume in the participants after the
      use of the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum creatinin</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The change of Serum creatinin from baseline after the use of the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The change of eGFR from baseline after the use of the study drug. eGFR (ml/min/1.73m2)=K×L/SCr. L: Height(cm), SCr: serum creatinin (umol/L),K:36.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine volume</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The change of urine volume from baseline after the use of the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary markers：White Blood Cell (WBC)</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through routine urine examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary markers：Red Blood Cell (RBC)</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through routine urine examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary markers：Urine protein</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through routine urine examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum urea</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through renal function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cystatin</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through renal function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three dimensional(3D) color ultrasound Imaging</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Size of kidneys,Blood flow of renal arteries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stays</measure>
    <time_frame>baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Children AKI Patients</condition>
  <arm_group>
    <arm_group_label>Alprostadil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Ferulate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil</intervention_name>
    <description>Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d</description>
    <arm_group_label>Alprostadil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Ferulate</intervention_name>
    <description>Sodium Ferulate 2~6mg/kg.d,iv,14d</description>
    <arm_group_label>Sodium Ferulate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopamine</intervention_name>
    <description>Dopamine3～5 ug/kg·min,iv,3 h/d,14d</description>
    <arm_group_label>Alprostadil</arm_group_label>
    <arm_group_label>Sodium Ferulate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide informed consent signed and dated by participants and/or their guardians

          2. male or female, Asian.

          3. Aged from 1 to 18 years.

          4. Patients meet the AKI diagnosis criteria of 2012 Kidney Disease: Improving Global
             Outcome (SKDIGO) Guideline

        Exclusion Criteria:

          1. prerenal or postrenal failure

          2. Patients need renal replacement therapy

          3. Patients with hemorrhagic disorders

          4. Patients in shock

          5. Patients with multiple organ failure

          6. History of Alprostadil or Sodium Ferulate or dopamine sensitivity

          7. Patients with heart failure

          8. Patients with peptic ulcer

          9. Patients with glaucoma

         10. Patients with interstitial pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yubin Wu, Professor</last_name>
    <phone>18940257958</phone>
    <email>wuyb001@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://kdigo.org/</url>
    <description>2012 SKDIGO Guideline</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Yubin Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>AKI</keyword>
  <keyword>Child</keyword>
  <keyword>Alprostadil</keyword>
  <keyword>Sodium Ferulate</keyword>
  <keyword>Dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferulic acid</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Dear Sir/Madam Our study receives a grant from China Ministry of Science and Technology. We cannot decide whether the data could be shared. Hope you can understand.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

